Maxine Jin

Guangdong Dtech Technology Co., Ltd., a leading integrated provider of precision manufacturing solutions for the global PCB fabrication value chain, on its HK$4.8 billion global offering and listing of H shares on the Main Board of the Hong Kong Stock Exchange. *
Morgan Stanley and CLSA Limited as the placing agents on the HK$472 million placing of new H shares of GenFleet Therapeutics (Shanghai), Inc., a biopharmaceutical company focused on developing innovative treatment solutions in the fields of oncology, autoimmune and inflammatory diseases, on the Main Board of the Hong Kong Stock Exchange. *
WuXi AppTec Co., Ltd., a global leading pharmaceutical R&D and manufacturing services company, on its issuance of RMB6.78 billion U.S. dollar-settled zero-coupon convertible bonds due 2027, with the bonds listed on the Vienna Stock Exchange. *
Guangdong Huayan Robotics Co., Ltd., a leading collaborative robotics company in China, on its HK$1.58 billion global offering and listing under Chapter 18C on the Main Board of the Hong Kong Stock Exchange. *
Star Sports Medicine Co., Ltd., a leading sports medicine medical device company in China, on its HK$830 million global offering and listing on the Main Board of the Hong Kong Stock Exchange.*
B&K Corporation Limited, a biopharmaceutical company focused on developing protein-based therapies for wound healing, on its HK$674 million global offering and listing under Chapter 18A on the Main Board of the Hong Kong Stock Exchange. *

Maxine JinMaxineJin